Obesity is a complex, chronic disease that requires long-term medical management, not simply greater willpower or lifestyle changes alone. According to the CDC (Centers for Disease Control and Prevention), 41.9% of U.S. adults are living with obesity, making it as prevalent as other chronic conditions like diabetes and hypertension.
For decades, the medical weight loss options available to treat have fallen short. Diets, gym memberships, and older weight-loss pills produced modest results and frequent gains.
That changed with GLP-1 medications. Ozempic, Wegovy, Zepbound, Mounjaro-the names get thrown around like they’re interchangeable, and that’s usually where the confusion starts. They’re not the same drug, they’re not approved for the same thing, and the differences matter once you’re the one holding the pen.
This guide covers what GLP-1 medications are, who qualifies, how they actually work in the body, what the research shows, what to expect physically, and how to think about cost and finding the right provider in Georgia. Consider it the one-page worth bookmarking before your first consultation.
GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. Its job: tell your brain you’re full, slow digestion, and help your pancreas manage blood sugar. GLP-1 medications are synthetic versions of that hormone, engineered to last for a full week rather than fading within minutes. That’s the entire trick behind a once-weekly injection.
| Medication | Active Drug | Mechanism | FDA-Approved For |
| Ozempic | Semaglutide | GLP-1 receptor agonist | Type 2 diabetes (weight-loss use is off-label) |
| Wegovy | Semaglutide | GLP-1 receptor agonist | Chronic weight management |
| Mounjaro | Tirzepatide | Dual GLP-1/GIP receptor agonist | Type 2 diabetes (weight-loss use is off-label) |
| Zepbound | Tirzepatide | Dual GLP-1/GIP receptor agonist | Chronic weight management, moderate-to-severe obstructive sleep apnea |
| Saxenda | Liraglutide | GLP-1 receptor agonist (daily) | Chronic weight management |
Most programs, including physician-led ones in Georgia, follow guidelines from the Obesity Medicine Association and the FDA’s approval criteria. You’re generally a medical weight loss candidate if:
BMI is a starting point, not the whole picture. Waist circumference, body composition, and metabolic labs matter too, which is why a real consultation looks at more than a single number on a chart.
GLP-1s aren’t the only prescription option, either.
The SURMOUNT-1 trial found that participants without diabetes who took the highest dose of tirzepatide lost an average of 22.5% of body weight over 72 weeks, more than triple what most pre-GLP-1 interventions achieved. Semaglutide’s STEP program showed an average weight loss of roughly 15% over 68 weeks. Both numbers dwarf the 5-8% range that diet-and-exercise-only programs have historically produced.
Real-world results tend to land a bit lower than trial results, since people skip doses or stop early. A realistic expectation for a well-managed program is 1-2 pounds per week on average during the first several months, with total loss in the 15-20% range over 12-18 months for patients who stay consistent.
There’s no universal answer here; it depends on health history, insurance, and what your provider thinks fits your goals. Ozempic and Wegovy both use semaglutide, but Ozempic is labeled for diabetes and Wegovy for weight loss, which shapes what insurance will cover and at what dose. Zepbound uses tirzepatide, acts on two hormone receptors rather than one, and tends to produce a larger average weight loss in head-to-head trials.
None of these is objectively “better” for every patient. A slower-acting option might suit someone especially sensitive to nausea, while someone focused purely on maximum weight loss might lean toward tirzepatide.
Cost and insurance formulary status often end up being the deciding factor as much as the clinical data, which is exactly why this decision belongs in a conversation with a provider.
GLP-1 medications aren’t a start-high-and-go situation. Every reputable prescriber starts low and increases the dose slowly, usually every 4 weeks, to give your GI system time to adjust. Tirzepatide typically starts at 2.5 mg weekly, a dose meant purely to acclimate your body rather than drive weight loss, before stepping up toward maintenance doses of 5 mg, 10 mg, or 15 mg based on tolerance and response. Semaglutide follows a similar stair-step pattern at its own dose intervals.
Rushing this process is one of the fastest ways to end up with severe nausea or vomiting, and it’s a common reason patients quit treatment early. A structured schedule, adjusted by a provider actually reviewing your side effects at each step, matters more than most patients expect going in.
| Common (usually improves in weeks) | Less Common (worth flagging to your provider) |
| Nausea, especially after a dose increase | Gallbladder issues |
| Constipation or diarrhea | Pancreatitis (rare) |
| Bloating, fatigue | Slowed heart rate |
| Occasional heartburn | Hair thinning (usually tied to rapid weight loss and low protein intake, not the drug itself) |
For a lot of patients, the needle is more intimidating than the medication itself. The injection is subcutaneous, meaning just under the skin, done with a very fine needle into the abdomen, thigh, or upper arm.
Rotating sites each week helps prevent irritation and the small, hard lumps that can build up if you inject the same spot repeatedly. Most modern pens are built for exactly this scenario, with guides that make site selection and depth nearly foolproof after a couple of tries. Storing pens properly, refrigerated until first use, then at room temperature for a limited window, also matters more than most patients realize for keeping the medication effective.
Without insurance, Zepbound can cost over $1,000 per month, depending on the prescribed dosage and pharmacy. At Windermere Medical Group, we understand that affordability is an important part of your medical weight loss journey.
During your consultation, our providers will discuss your treatment goals, review available medication options, explain pricing, and help you determine the most cost-effective solution based on your individual needs. Our goal is to make safe, physician-supervised weight loss treatment as accessible and manageable as possible.
Rapid, significant fat loss doesn’t just happen at the waistline; it happens in the face too. Cheeks hollow out, temples sink in, and skin that was stretched over a fuller face doesn’t always spring back on its own. The internet has dubbed this “Ozempic face,” and while the term is a little dramatic, the underlying phenomenon is real and well-documented among providers who regularly treat GLP-1 patients.
It’s manageable and often preventable with the right pacing. Slower titration, adequate protein intake, and, when needed, dermal fillers or skin-tightening treatments can restore facial volume and structure without requiring anyone to abandon their weight-loss progress.
This is one area where pairing medical weight loss with aesthetic support in the same practice genuinely helps, since the provider managing your dose can flag facial volume changes early rather than after the fact.
A real medical weight loss program follows a consistent structure, not a one-time script.
Initial consultation and assessment: A full review of medical history, current medications, and prior weight-loss attempts, plus baseline labs: thyroid function, HbA1c, a metabolic panel, and lipids at a minimum. At Windermere Medical Group, this visit also screens for thyroid and hormone issues, since undiagnosed insulin resistance or thyroid dysfunction is a common, often-missed piece of the weight puzzle.
Titration: Dose increases roughly every 4 weeks, with tolerability checks along the way. Most patients notice reduced appetite within the first two weeks; visible weight loss typically shows up between weeks four and eight.
Ongoing monitoring: Monthly visits for the first three months, then every 8-12 weeks thereafter, with repeat labs at the three- and six-month marks to confirm the medication is working safely. GLP-1 therapy is generally chronic therapy; stopping tends to bring appetite back, and studies consistently show meaningful weight gain within 12 months of discontinuation, so any decision to taper off is one to plan with your provider, not make alone.
A virtual clinic option covers follow-up visits and dose check-ins for patients who’d rather not drive in, while a same-day clinic handles the visits that can’t wait. For a chronic therapy that’s meant to last well over a year, that kind of flexibility ends up mattering as much as the medication itself.
Georgia’s GLP-1 market has gotten crowded fast; telehealth startups, medspas, weight-loss chains, and traditional medical practices are all competing for the same patients. A few questions cut through the noise quickly:
| Question to Ask | What a Strong Answer Sounds Like |
| Who actually reviews my case? | A licensed physician, not just a form and an algorithm |
| What labs do you run before starting? | Metabolic panel, thyroid, HbA1c, lipids, at minimum |
| How do you handle side effects? | A clear escalation plan and access to your prescribing provider |
| Where does the medication come from? | A licensed pharmacy, clearly disclosed, brand or compounded |
| What happens after I hit my goal weight? | A maintenance plan, not a sudden stop |
At Windermere Medical Group, obesity management is integrated into a full primary and chronic care practice rather than a standalone side business. The same team managing a GLP-1 dose can also manage thyroid, blood pressure, or diabetes when those conditions are part of the picture, which, for a lot of patients starting this journey, they are.
Dr. Priya Bayyapureddy, MD, a board-certified internal medicine physician and diplomate of the American Board of Obesity Medicine, oversees care alongside a team that includes Family Medicine and obesity-trained providers.
With locations across Cumming, Canton, Alpharetta, Lawrenceville, Baldwin, and Gainesville, plus a Virtual Clinic and Same Day Clinic option, care fits around a patient’s schedule rather than the other way around.
GLP-1 medications didn’t create a shortcut for medical weight loss; they created a tool that finally matches the biology of obesity instead of fighting it with willpower alone. Used well, under real medical supervision, they’re producing results that simply weren’t possible a decade ago. Used carelessly, without labs, titration, or follow-up, they’re just an expensive way to feel nauseous.
The difference almost always comes down to who’s managing the care. If you’re in Cumming, Canton, Alpharetta, Lawrenceville, Baldwin, Gainesville, or anywhere in between, Windermere Medical Group’s physician-led obesity management program is built to give patients the full picture, labs, monitoring, hormone screening, and a provider who’s actually board-certified in obesity medicine, not just a prescription.
GLP-1 medications mimic a gut hormone that signals fullness to your brain, slows stomach emptying, and helps regulate blood sugar. The result is reduced appetite, longer satiety, and gradual, sustained weight loss.
Zepbound (tirzepatide) has produced the greatest weight-loss results in clinical trials, followed by Wegovy (semaglutide). The best option for you depends on your individual response, insurance coverage, and tolerance. A consultation is the only reliable way to determine which is right for your situation.
Most patients notice reduced appetite within two weeks of starting. Visible weight loss typically begins between weeks 4 and 8, with peak results at 12-18 months of consistent use at the therapeutic dose.
Prioritize protein (100 to 130 grams per day for most adults), plenty of fiber, and adequate hydration. Smaller, more frequent meals are often easier to tolerate than large ones. Avoid high-fat and greasy foods, especially during dose increases, as they tend to worsen nausea.
Program costs vary based on the medication prescribed, your insurance coverage, and the level of support included. Consultations at Windermere include a detailed cost estimate before you commit to a treatment plan.
Medicare does not cover GLP-1 medications for weight loss alone. It does cover them for type 2 diabetes and, in specific cases, for cardiovascular risk reduction in patients with obesity and established heart disease.
Coverage typically requires meeting BMI criteria (30 or 27 with comorbidities), documented prior weight loss attempts, and a completed prior authorization. Our team submits and manages this process on your behalf, which is often the deciding factor in whether coverage is approved.
Compounded semaglutide is legal only under specific FDA rules and is subject to important quality and safety considerations. See our full guide on compounded GLP-1 medications for the current legal and clinical landscape.
Yes, most patients regain a significant portion of the weight within 12 months of stopping. GLP-1 is a chronic therapy. Any decision to discontinue should be planned collaboratively with your provider.
Yes, in most cases. Metformin and GLP-1 medications are frequently prescribed together for patients who have both type 2 diabetes and obesity. Always confirm the combination with your prescribing physician.
Dr. Priya Bayyapureddy, MD is a board certified Internal Medicine doctor with over 20 years of experience in primary care Internal Medicine. Dr. Bayyapureddy completed her Internal Medicine residency at Emory University School of Medicine and internship at University of Tennessee College of Medicine at Chattanooga.
Recent Post